The Annual Land O’ Lakes Bioanalytical Conference discusses innovations, challenges, and applications associated with the analysis of xenobiotics, metabolites, biologics, and biomarkers in biological matrices.
This year, the conference explores the extension of foundational principles to accommodate new technologies, modalities, and ways of working that support innovative modalities and programs. Attendees will discuss challenges and solutions related to the analysis of new therapeutic modalities (gene and cell therapy, multi-domain therapeutics, nucleic acids, encapsulated products, etc.); technology platforms; sample collection techniques; and the associated regulatory aspects that come from novel research applications.
- Share best practices and case studies for designing a successful bioanalytical plan with limited precedent
- Discuss strategies for overcoming assay challenges and engaging scientists from multiple disciplines in troubleshooting
- Share examples and suggestions for how to design appropriate validation experiments in the absence of formal guidance through case studies
- Highlight new considerations for assay life cycle management
Stephanie Cape, Ph.D., Labcorp Drug Development (Chair)
Vibha Jawa, Ph.D., Bristol-Myers Squibb Company, (Vice Chair)
Chad Briscoe, Ph.D. BioAgilytix (Past Chair)
Sanjeev Bhardwaj, Ph.D., Janssen/Johnson & Johnson
Eric Buxton, Ph.D., University of Wisconsin-Madison
Todd Lester, B.S. Biological Sciences, BioAgilytix
Sriram Subramaniam, Ph.D. U.S. Food and Drug Administration (FDA)
Martin Ullmann, Ph.D., Fresenius-Kabi
Catherine Vrentas, Ph.D., Pharmaceutical Product Development (PPD)
Christine Weisshaar, MS, Spark Therapeutics